Antiplatelet effect of the pyrimido-pyrimidinic derivative RA-642.
de la Cruz
J P
JP
Department of Pharmacology and Therapeutics, School of Medicine, University of Málaga, Spain.
Moron
D
D
Sanchez de la Cuesta
F
F
D000241:Adenosine / Q000097:blood; D002316:Cardiotonic Agents / Q000494:pharmacology*; D004176:Dipyridamole / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D009012:Mopidamol / Q000494:pharmacology*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D013806:Theophylline / Q000097:blood
D002316:Cardiotonic Agents; D010975:Platelet Aggregation Inhibitors; D011743:Pyrimidines; D009012:Mopidamol; C010650:RA 642; D004176:Dipyridamole; D013806:Theophylline; D000241:Adenosine